Abeona Therapeutics Acquires EoE Drug Candidate From Ellodi for $20 Million in Stock

• Abeona Therapeutics acquired EoE candidate APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals for $20 million in common stock, with no upfront cash.
• Ellodi is eligible for $30 million upon FDA approval, up to $30 million in sales milestones, and low-to-mid-teens royalties on net sales.
• ABO-801 is a once-daily oral therapy candidate for eosinophilic esophagitis, with FDA Orphan Drug and Fast Track designations.
• Neither completed Phase 3 study met its prespecified co-primary patient-reported symptom endpoint; both showed statistically significant improvements in several endoscopic measures.
• A planned Phase 3 study is expected to begin in mid-2027, with topline results anticipated by end-2028, subject to initiation and enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090630PRIMZONEFULLFEED9873179) on November 09, 2026, and is solely responsible for the information contained therein.